Biosimilars Portfolio

About lupin

Lupin is a mission-driven global pharmaceutical company focused on improving access to essential and advanced medicines through the development and commercialization of generic drugs, complex formulations, and biosimilars. Founded in 1968, it has grown into a top-tier generics player with a significant presence in the US, India, and other key markets, underpinned by robust R&D and manufacturing capabilities. Its strategy centers on expanding its complex generics and specialty portfolio, advancing its biosimilars pipeline, and leveraging operational excellence to drive sustainable, long-term growth.

About Kidswell Bio

Japanese biotech developing SHED-based cell therapies for pediatric neurological disorders and operating a dual business model with biosimilars.

About Gulf Pharmaceutical Industries

Julphar's mission is to provide a better quality of life by delivering best-in-class, accessible pharmaceutical solutions. The company has achieved a position as one of the largest generic drug producers in the MEA region, with a commercial footprint spanning over 50 countries and state-of-the-art manufacturing facilities. Its strategy is centered on expanding its portfolio of complex generics and biosimilars, supported by strategic partnerships and a focus on operational excellence to drive revenue growth and margin expansion.

Therapeutic Areas

Other Oncology, Immunology Drugs